ADMA Class Action Notice: ADMA Biologics Hit with Securities Fraud Lawsuit over Channel Stuffing Misrepresentations – Investors Urged to Contact BFA Law by August 10 Deadline
Bleichmar Fonti & Auld LLP announced a class action lawsuit against ADMA Biologics alleging securities fraud related to a channel stuffing scheme. The complaint references a Culper Research report claiming ADMA’s reported 20% growth was inflated by undisclosed distributor incentives that masked a 3% revenue decline.
Key figures
- Lead Plaintiff Deadline
- August 10, 2026
- Case number
- 26-cv-6918
- Stock drop mar 24
- 16.6%
- Stock drop mar 25
- 15%
- Stock drop mar 29
- 13.9%
- Alleged real growth 2025
- -3%
- Alleged reported growth 2025
- 20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.